Sanofi (SNY) Stock Price & Analysis
Sanofi (SNY) closed at USD 41.96 on Thursday, October 22, 2026, up 2.42% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 40.97; the Oct 22, 2026 session ranged USD 41.07–42.11 on volume of 3,458,774 shares. Market capitalization is $100.54B, with a 52-week range of USD 39.07–52.68 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SNY.md
Key facts (SNY)
- 4 of 80 tracked superinvestors hold SNY (13F, Q2 2026): 0 new, 2 added, 2 reduced, 0 unchanged.
- Analysts: Hold (mean 2.55 on a 1–5 scale) (11 analysts), mean target USD 53.61 (range 44–63).
- Total return with dividends: 1Y -10.6% vs S&P 500 +14.9%; 5Y +4.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 1.51, revenue estimate $13.3B.
Superinvestors (SEC 13F-HR, Q2 2026) (SNY)
4 of 80 tracked investors hold SNY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 0.63% | $1.20B | Reduced -4.8% |
| Sarah Ketterer | Causeway Capital Management | 0.37% | $34.3M | Reduced -24.5% |
| Lee Ainslie | Maverick Capital | 0.02% | $2.2M | Added +109.8% |
| Richard Pzena | Pzena Investment Management | <0.01% | $1.1M | Added +32.5% |
Analysts (SNY)
Consensus Hold (mean 2.55 on a 1–5 scale), 11 analysts; mean target USD 53.61 (low 44, high 63).
Total return (dividends reinvested) (SNY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -10.6% | +4.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -10.6% | +0.8% |
| Volatility (annualized) | 23.1% | 24.7% |
| Max drawdown | -21.1% (Nov 2025→Oct 2026) | -31.1% (May 2022→Sep 2022) |
Companies that name SNY in their SEC reports
| Relationship to SNY | Company | Filing | Sentence |
|---|---|---|---|
| customer | Pharming Group N.V. (PHAR) | 20-F Apr 2, 2026 | “We have entered into (downstream) manufacturing and supply agreements for Joenja® and RUCONEST® with, among others, Sanofi S.A., or Sanofi, and BioConnection Investments B.V. (formerly BioConnection B.V.), or BioConnection, since we do not have GMP drug substance and drug product manufacturing and lab facilities to produce and test the product.” |
| partner | Adagene Inc. (ADAG) | 20-F Apr 1, 2026 | “Sanofi Collaboration and Technology License Agreement” |
| partner | Entera Bio Ltd. (ENTX) | 10-K Mar 27, 2026 | “She currently serves as the Head of Sanofi's Strategic Partnership and Portfolio Planning where she is responsible for increasing franchise growth and profitability.” |
| customer | DBV Technologies S.A. (DBVT) | 10-K Mar 26, 2026 | “We also expect to rely on Sanofi and on FAREVA for the manufacturing of the patch and on other third-party manufacturers for the manufacturing of commercial supply of Viaskin Peanut, if approved, and any other product for which we obtain regulatory approval.” |
| partner | Inhibrx Biosciences, Inc. (INBX) | 10-K Mar 19, 2026 | “In connection with the Separation, the Company also entered into the Transition Services Agreement with the Former Parent under which the Company or one of its affiliates provide the Former Parent or other Sanofi entities with certain transition services for a limited time to ensure an orderly transition following the Separation.” |
| partner | Vaxart, Inc. (VXRT) | 10-K Mar 13, 2026 | “There can be no assurance that Sanofi will continue to perform the obligations under the 2025 License and Collaboration Agreement or that Sanofi will not exercise its right to terminate the agreement.” |
| partner | MACROGENICS INC (MGNX) | 10-K Mar 9, 2026 | “In April 2023, Sanofi S.A. completed its acquisition of Provention and the Company entered into a tripartite agreement with DRI and Sanofi under which it was released of any obligations under the Royalty Purchase Agreement.” |
| partner | Kymera Therapeutics, Inc. (KYMR) | 10-K Feb 26, 2026 | “We are collaborating with Sanofi S.A. ("Sanofi") on the development of our IRAK4 degrader, KT-485/SAR447971, which Sanofi plans to advance into clinical testing in 2026.” |
| partner | Denali Therapeutics Inc. (DNLI) | 10-K Feb 26, 2026 | “As part of our parallel development strategy, we have also developed peripherally-restricted RIPK1 inhibitor molecules, which are included as part of the collaboration agreement with Sanofi, described in more detail in "Business - Licenses and Collaborations" below.” |
| partner | RECURSION PHARMACEUTICALS, INC. (RXRX) | 10-K Feb 25, 2026 | “To date, we have received over $500 million in partner payments for novel data generation (e.g. maps optioned by Roche and Genentech) and advancing AI-designed small molecule programs with Sanofi and others.” |
| partner | Schrodinger, Inc. (SDGR) | 10-K Feb 25, 2026 | “Our current collaborators include, but are not limited to, Ajax Therapeutics, Inc., BMS, Bright Angel Therapeutics Inc., Lilly, Novartis, Otsuka Pharmaceutical Co., Ltd., or Otsuka, Sanofi S.A., and Structure Therapeutics Inc. (formerly ShouTi, Inc.).” |
| partner | Merck & Co., Inc. (MRK) | 10-K Feb 24, 2026 | “The Company manufactures a hepatitis B vaccine (Recombivax HB, Hepatitis B Vaccine [Recombinant]) and, subject to a collaboration agreement with Sanofi Pasteur MSD, co-promotes a hexavalent vaccine that includes a hepatitis B component (Vaxelis, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).” |
| partner | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | 10-K Feb 12, 2026 | “Qfitlia (fitusiran) is being commercialized by our collaborator, Genzyme Corporation, a Sanofi Company, or Sanofi, and was approved by the FDA in March 2025 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B, with or without factor VIII or IX inhibitors (neutralizing antibodies), and by China's National Me…” |
| partner | NEUROCRINE BIOSCIENCES INC (NBIX) | 10-K Feb 11, 2026 | “In 2014, we entered into a license agreement with Sanofi, pursuant to which we acquired the global rights to develop and commercialize certain corticotropin-releasing factor type 1 (CRF-1) receptor antagonists, including crinecerfont.” |
| partner | Nurix Therapeutics, Inc. (NRIX) | 10-K Jan 28, 2026 | “Our partnered drug discovery pipeline consists of a clinical stage degrader of IRAK4 (NX-0479/GS-6791), a preclinical stage degrader of STAT6, currently in investigational new drug application (IND), enabling studies, and multiple currently undisclosed targets under collaboration agreements with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi) and Pfizer Inc. (Pfizer).” |
SNY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.51 | $1.60 | -5.3% | $13.28B | 2 |
| Next quarter (ends Dec 2026) | $1.12 | $1.02 | +10.3% | $12.79B | 2 |
| Current fiscal year (ends Dec 2026) | $4.93 | $4.79 | +3.0% | $47.56B | 6 |
| Next fiscal year (ends Dec 2027) | $5.28 | $5.14 | +2.8% | $50.67B | 6 |
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 41.96 |
|---|---|
| Change | ▲ 2.42% (up) |
| Previous Close | USD 40.97 |
| Open | USD 41.17 |
| Day Range | USD 41.07 – 42.11 |
| 52-Week Range | USD 39.07 – 52.68 |
| Volume | 3,458,774 shares |
| Market Cap | $100.54B |
| Exchange | NMS |
Technical Analysis (SNY)
Nexqual's technical model rates SNY "NEUTRAL" based on 3 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 54.31 (neutral) |
| vs SMA50 | Below (USD 42.46) |
| MACD | -0.35 (negative) |
Analyst Ratings (SNY)
Wall Street analysts rate SNY "Hold" based on 11 analysts, with a mean price target of USD 53.61 (range USD 44–63), per Nexqual as of October 23, 2026 at 09:27 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 53.61 |
| High Target | USD 63 |
| Low Target | USD 44 |
| Buy / Hold / Sell | 5 / 6 / 0 |
Earnings (SNY)
| Next Earnings Date | 2026-10-30 |
|---|---|
| EPS Estimate | USD 1.51 |
| Revenue Estimate | $13.28B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.2 vs est 1.14 ▲ beat |
| 2026-03-31 | USD 1.1 vs est 1.03 ▲ beat |
| 2025-12-31 | USD 0.91 vs est 0.85 ▲ beat |
| 2025-09-30 | USD 1.69 vs est 1.57 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (SNY)
| Total Revenue | $48.92B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +14.60% |
| Gross Margin | +73.45% |
| Operating Margin | +21.03% |
| Profit Margin | +8.09% |
| ROE | +5.71% |
| Debt / Equity | 0.34 |
| Current Ratio | 0.99 |
| Total Cash | $6.35B |
| Total Debt | $23.58B |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Ownership (SNY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +8.01% |
| Shares Outstanding | 2.40B |
| Float | 2.16B |
| Short % of Float | +0.50% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Leadership (SNY)
Sanofi is led by Belen Garijo Lopez, CEO & Director, per Nexqual as of October 23, 2026 at 09:27 UTC.
| CEO & Director | Belen Garijo Lopez |
|---|---|
| Executive VP & CFO | François-Xavier Roger |
| Chief Scientific Officer & Head of Research | Michael Quigley |
| Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | Pierre Chancel |
| Executive Vice President of Vaccines | Thomas Triomphe |
Major Backers & Investors (SNY)
Notable institutional backers of Sanofi include Dodge & Cox Inc., Morgan Stanley, Fisher Asset Management, LLC, according to Nexqual as of October 23, 2026 at 09:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 10.54% |
| Morgan Stanley | 4.02% |
| Fisher Asset Management, LLC | 3.99% |
| Bank of America Corporation | 3% |
| Invesco | 2.55% |
| JPMorgan | 2.47% |
| Mondrian Investment Partners Ltd | 2.07% |
| Brandes Investment Partners L.P. | 1.55% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GSK | GSK plc | USD 51.21 | ▲ 2.38% |
| BMY | Bristol-Myers Squibb Company | USD 63 | ▲ 3.08% |
| PFE | Pfizer, Inc. | USD 30.42 | ▲ 1.91% |
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt